Magazine Article | January 2, 2019

Germany's Plan To Foster And Grow Biopharma Innovation

Source: Life Science Leader

By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter

In Germany, like many other developed markets, net growth in pharmaceuticals has slowed or is declining, according to 2018 figures from IQVIA. There has been a shift toward specialty pharmaceuticals, however. Specialty medicines represented 39 percent of spending in the 10 developed markets, with Germany as one of the major drivers. To ensure the continued growth of the industry, particularly the specialty pharmaceuticals industry, innovation needs to be encouraged and supported. This is the role of the bioclusters and technology parks across Germany.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: